Synektik

Synektik Net Debt / EBITDA

The Net Debt to EBITDA of Synektik (SNT.WA) as of Oct 31, 2026 is -0.28. In the previous year, Net Debt to EBITDA was -0.56 — a change of -49.89% (higher).

Net Debt / EBITDA

-0.28

YoY

-49.89%

Last updated:

Net Debt to EBITDA of Synektik is 2025 -0.28 . Net Debt to EBITDA of Synektik was 2024 -0.56 . It decreases by -49.89% higher compared to the previous year.

The Synektik Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2018
0.94 PLN
Jan 1, 2019
0.28 PLN
Jan 1, 2020
0.81 PLN
Jan 1, 2021
-0.01 PLN
Jan 1, 2022
3.70 PLN
Jan 1, 2023
-0.66 PLN
Jan 1, 2024
-0.56 PLN
Jan 1, 2025
-0.28 PLN
The Synektik Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
-0.28-49.89%
-0.56-15.13%
-0.66-117.83%
3.70-40,438.84%
-0.01-101.14%
0.81+183.53%
0.28-69.57%
0.94-120.58%
-4.54+308.74%
-1.11-105.45%
20.40-1,118.02%
-2.00-61.39%
-5.19-80.40%
-26.48-236.24%
19.43-430.01%
-5.89—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Synektik Stock analysis

What does Synektik do? Synektik SA generates revenue through its PACS software, which enables diagnostic imaging laboratories to operate efficiently. The company also sells medical equipment and provides services through its imaging equipment services center. Synektik SA partners with Siemens and holds a 100% stake in Miedzynarodowe Centra Medyczne Inwestycje Sp z o o, which it acquired by raising its stake on November 28, 2013. The firm's research laboratory conducts acceptance and specialist tests on X-ray equipment, contributing to its service offerings. The primary buyers of Synektik SA's products include diagnostic imaging laboratories that require PACS software for their operations. Medical equipment is sold to healthcare facilities, while the research laboratory services are utilized by entities needing X-ray equipment testing. The company's partnership with Siemens supports its medical equipment sales and services. Synektik SA's revenue streams are derived from software licensing, medical equipment sales, and specialized testing services. The company's focus on diagnostic imaging solutions and its ownership of Miedzynarodowe Centra Medyczne Inwestycje Sp z o o position it within the medical technology sector, targeting healthcare providers and imaging laboratories. Synektik is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Synektik stock

Net Debt to EBITDA of Synektik is -0.28 in 2025.

Net Debt to EBITDA of Synektik changed from -0.56 to -0.28, representing a -49.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Synektik since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Synektik with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Synektik

All Key Metrics — Synektik